Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | FABP4 | P15090 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PKLR | P30613 | 1/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15998983 | 0.89 | RECQL (0.54) | ALDH1A1KDM4EHSD17B10LMNAFABP4 | |
| SCHEMBL3116842 | 0.86 | CHRM1 (0.52) | ALDH1A1HSD17B10TP53LMNAFABP4 | |
| SCHEMBL15999052 | 0.84 | PTGER4 (0.50) | ALDH1A1KDM4EFABP4SMN1; SMN2PKM | |
| SCHEMBL15997707 | 0.84 | LMNA (0.45) | ALDH1A1KDM4ELMNASMN1; SMN2HTT | |
| SCHEMBL15999090 | 0.81 | USP2 (0.46) | ALDH1A1KDM4EHSD17B10RECQLPKM | |
| SCHEMBL30622483 | 0.80 | HPGD (0.41) | ALDH1A1KDM4EHSD17B10NPC1LMNA | |
| SCHEMBL12499414 | 0.80 | RECQL (0.53) | ALDH1A1KDM4EHSD17B10LMNASMN1; SMN2 | |
| SCHEMBL26603232 | 0.79 | FABP4 (0.48) | ALDH1A1KDM4EGAAHSD17B10TP53 | |
| SCHEMBL15687379 | 0.78 | RECQL (0.48) | ALDH1A1TP53NPC1LMNASMN1; SMN2 | |
| SCHEMBL30729366 | 0.78 | BRD4 (0.49) | ALDH1A1KDM4EGAARECQLPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250088-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250088-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | ALDH1A1 4633/4885KDM4E 3667/4885GAA 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.